0001567619-19-007339.txt : 20190321 0001567619-19-007339.hdr.sgml : 20190321 20190321130712 ACCESSION NUMBER: 0001567619-19-007339 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20190321 DATE AS OF CHANGE: 20190321 EFFECTIVENESS DATE: 20190321 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NERVGEN PHARMA CORP. CENTRAL INDEX KEY: 0001751912 IRS NUMBER: 000000000 STATE OF INCORPORATION: A1 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-335393 FILM NUMBER: 19696487 BUSINESS ADDRESS: STREET 1: SUITE 1703 - 595 BURRARD STREET CITY: VANCOUVER STATE: A1 ZIP: V7X 1J1 BUSINESS PHONE: 6047225361 MAIL ADDRESS: STREET 1: SUITE 1703 - 595 BURRARD STREET CITY: VANCOUVER STATE: A1 ZIP: V7X 1J1 D 1 primary_doc.xml X0708 D LIVE 0001751912 NERVGEN PHARMA CORP. SUITE 1703 - 595 BURRARD STREET VANCOUVER A1 BRITISH COLUMBIA, CANADA V7X 1J1 (604) 722-5361 BRITISH COLUMBIA, CANADA None None Corporation true 2017 William Joseph Radvak Suite 1703 - 595 Burrard Street Vancouver A1 BRITISH COLUMBIA, CANADA V7X 1J1 Executive Officer Director Robert Pilz Suite 1703 - 595 Burrard Street Vancouver A1 BRITISH COLUMBIA, CANADA V7X 1J1 Executive Officer Ernest Wong Suite 1703 - 595 Burrard Street Vancouver A1 BRITISH COLUMBIA, CANADA V7X 1J1 Executive Officer Director Michael Jeffrey Abrams Suite 1703 - 595 Burrard Street Vancouver A1 BRITISH COLUMBIA, CANADA V7X 1J1 Director Brian Bayley Suite 1703 - 595 Burrard Street Vancouver A1 BRITISH COLUMBIA, CANADA V7X 1J1 Director Harold Punnett Suite 1703 - 595 Burrard Street Vancouver A1 BRITISH COLUMBIA, CANADA V7X 1J1 Director Other Decline to Disclose 06b false 2019-03-13 false true false 0 Haywood Securities Inc. None Haywood Securities (USA) Inc. 42072 700 - 200 Burrard Street Vancouver A1 BRITISH COLUMBIA, CANADA V6C 3L6 AK ALASKA CA CALIFORNIA CT CONNECTICUT FL FLORIDA GA GEORGIA HI HAWAII IL ILLINOIS LA LOUISIANA MI MICHIGAN NC NORTH CAROLINA NJ NEW JERSEY NV NEVADA NY NEW YORK TX TEXAS VA VIRGINIA WA WASHINGTON false 1196500 1196500 0 false 28 83755 0 In addition to cash, the agents may receive up to 111,691 warrants; each warrant may be exercised for 1 common share at a price of CDN$1.00 per share until March 13, 2021. 0 false NERVGEN PHARMA CORP. /s/ Robert G. Pilz Robert G. Pilz Chief Financial Officer 2019-03-20